Acotiamide-d4

Acotiamide-d4 (Z-338 (free base) -d4) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory[1][2][3].

Product Specifications

Product Name Alternative

Z-338 (free base) -d4; YM443 (free base) -d4

UNSPSC

12352005

Target

Cholinesterase (ChE) ; Isotope-Labeled Compounds

Related Pathways

Neuronal Signaling; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C(NC([2H])(C([2H])(N(C(C)C)C(C)C)[2H])[2H])C1=CSC(NC(C2=CC(OC)=C(C=C2O)OC)=O)=N1

Molecular Formula

C21H26D4N4O5S

Molecular Weight

454.58

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kazuyoshi Y oshii, et al. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. Pharmaceutical Research, 33 (2), 292–300.|[3]Hiroshi Yamawaki, et al. Acotiamide attenuates central urocortin 2-induced intestinal inflammatory responses, and urocortin 2 treatment reduces TNF-α productions in LPS-stimulated macrophage cell lines. Neurogastroenterol Motil. 2020 Aug;32 (8) :e13813.|[4]Matsunaga Y, Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011 Mar;336 (3) :791-800.